Annovis Bio, Inc. (XNYS: ANVS) Stock Information | RedChip

Annovis Bio, Inc. (XNYS: ANVS) Listen to this Section


$8.92
+1.1600 ( +14.95% ) 661.9K

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Market Data


Open


$8.92

Previous close


$7.76

Volume


661.9K

Market cap


$98.87M

Day range


$8.00 - $9.57

52 week range


$4.53 - $22.49

Insider Ownership Transactions

Total Amount Purchased: -331,179.00 | $ -2,954,116.68

Date Type Amount Purchased Purchaser
2024-07-03 Sale -26200.00 White Mark K.
2024-07-03 Sale -29600.00 McCarthy Reid
2024-07-03 Sale -10000.00 Maccecchini Maria-Luisa
2024-07-03 Sale -29600.00 Hoffman Michael B
2024-07-03 Sale -26200.00 Bruck Claudine
2023-11-21 Sale -824.00 McCarthy Reid
2023-11-21 Sale -164745.00 Hoffman Michael B
2023-11-21 Sale -2000.00 White Mark K.
2023-11-21 Sale -41186.00 Maccecchini Maria-Luisa
2023-11-21 Sale -824.00 Hagopian Henry III

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 14 Aug 15, 2024
10-q Quarterly Reports 63 Aug 14, 2024
8-k 8K-related 16 Aug 06, 2024
8-k 8K-related 14 Jul 16, 2024
8-k 8K-related 13 Jul 10, 2024
4 Insider transactions 1 Jul 03, 2024
4 Insider transactions 1 Jul 03, 2024
4 Insider transactions 1 Jul 03, 2024
4 Insider transactions 1 Jul 03, 2024
4 Insider transactions 1 Jul 03, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.